AI USE LOG — TBI/TSPO PET TRACER PROJECT

ORIGINAL WEIGHTING SCHEME
ChatGPT - OpenAI, 5.2 version
Prompt:

“for the statistical weighting scheme at the beginning - - BPND: 0.32
- VT/fP: 0.18
- VT: 0.08
- VND inverse: 0.05
- Docking: -0.20 (according to directional changes - the more negative the better)
- pKi: 0.10
- logD closeness: 0.05
- fP: 0.02
- K1: 0.00
- Generate a full z-score normalization containing these study-defined heuristic weights to arrive at the top second-generation TSPO tracer for modification.


ENUMERATION
ChatGPT - OpenAI, 5.2 version
Prompt:

Envs: tspo-tracer2 (RDKit/OpenBabel), tspo-tracer (AutoDock Vina)

Key dirs:

docking/TSPO/ (TSPO_prepped.pdbqt → TSPO_receptor.pdbqt)

docking/emap_enum_round2/ (112 SDFs + PDBQTs, logs, out files)

figures/ (plots/leaderboards)

src/ (enumeration + rendering scripts)

Latest docking run target: docking/results_round2.csv (+ _failures.csv)

Scoring: R pipeline with equal-weighted z’s across Ki, PET metrics, docking, logD7.4 (custom weights available)

Lead scaffold: AC-5216 (emapunil) with R-group enumeration (round 2)


We are done with docking for round 2, but I feel like it is good to go for round 3. We got two results below -7 kcal/mol which is much better than the past run, and I would like to see if we can possibly make some fluorinated analogs or add silicon to analogs as well (silyl ethers and trifluoromethyl ethers in particular), if the tracer's effects are more pronounced in those cases. Currently the highest results are emap2_Bn-3__4diF_CH2CF3,-6.932, emap2_Bn-3__5diF_CH2CF3,-7.028, emap2_Bn-4Br_CH2CF3,-6.740, emap2_Bn-4CF3_CH2F,-6.924, emap2_Bn-4CF3_iPr,-6.947, emap2_Bn-4SF5_CH2CF3,-7.046, emap2_Bn-4SF5_CHF2,-6.901. The rest are quite mediocre. In order to jog your memory, here is an abstract of this project: Background: Traumatic brain injury currently remains as one of the most prevalent neurological conditions, with more than 50 million cases worldwide. The condition can be caused by any major injury to the skull, such as car accidents, sports injuries, and military injuries. The most common demographics affected by TBI include sportspeople in contact sports such as football, motorsport, and martial arts, and soldiers stationed in active combat and blast zones. Despite its magnitude, however, TBI is one of the least understood neurodegenerative conditions, especially at a molecular and histological level.

Current Literature: The current understanding of this molecular damage mainly includes the activation of microglia, which secrete neuroinflammatory biomarkers such as neurofilament light chain (NfL) and other proteins that collect near the injury site. Conventional structural approaches lack the capability of detecting molecular and diffuse damage, hence researchers now turn to molecular imaging in the form of positron emission tomography (PET imaging). Researchers employ ligands and binding agents known as radiotracers that bind to key biomarker proteins to visualize the diffuse damage that occurs in TBI.

Rationale: In this project, the main biomarker targeted is the human 18 kDa translocator protein (TSPO), a key binding protein expressed in traumatic brain injury. TSPO was chosen for its unique ability to visualize diffuse damage in the brain at specific points in TBI phases (acute, subacute, and chronic). According to current literature, TSPO peaks as early as 2-3 days post-injury allowing for acute detection, 28 days post-injury during the subacute phase, and again 17 years post-injury (as shown in an NFL study), during the chronic phase, making a possible future direction of this research be chronic traumatic encephalopathy diagnostics. ****However, while TSPO has multiple radiotracers used for visualization of other neurodegenerative conditions (e.g. Alzheimer’s and multiple sclerosis), TSPO currently does not have a radiotracer specifically optimized for TBI purposes. We are also testing out a new haloalkylation rationale specifically focusing on fluorine mods to existing TSPO PET tracer cores.

Objective: The main objective of this research project is to synthesize a radiotracer that can bind to TSPO’s peripheral benzodiazepine receptor (which is upregulated in microglial activation), specifically modified and optimized for use in traumatic brain injury. I developed a computational pipeline that normalizes PET metrics (VT, BP_ND, VND, VT/fP, and VND/fP), inhibition constant values (Ki), and docking energies from molecular docking analysis into z-scores with weights specifically tuned for TBI.

Results (so far): 8 tracers were selected for this statistical analysis (PK11195, PBR28, PBR06, PBR111, DAA1106, AC-5216, DPA713, and GE-180), on the basis of reliable human data and pharmacokinetics. Out of these tracers, 11C-AC-5216, also known as emapunil scored the highest in the z-score normalization, due to superior Ki and docking energy results. The tracer, however, is currently primarily used for Alzheimer’s and multiple sclerosis imaging, and required further modifications for optimization for TBI. For this reason, I permuted the first two functional groups, and successfully enumerated 144 emapunil analogs that have been processed and docked in the same computational pipeline, and will be organized by z-score. The top hit will then proceed to a pharmacokinetic pipeline, where ADME properties will be evaluated for the tracer, and therapeutic application of the tracer in specific areas of TBI would be researched further. Through z-score, the top hit should give us a clear novel radiotracer specifically optimized for applications in traumatic brain injury.

Future Directions: The next step in this research would be synthesis of the novel radiotracer. This would include the fluorination of specific R-groups for better binding potential and affinity to key radioisotopes 11C and 18F. Then, in vitro testing would occur using the shake-flask method of combining octanol and PBS buffer (7.4 pH) to have the optimal environment for tracer binding to TSPO. If possible, the next step would be radiolabeling of the tracer in wet lab, through nuclear magnetic resonance (NMR), with a pilot label of either **N-[^11C]methyl** or **aryl/^18F-fluoroalkyl** depending on the best possible synthesis guideline (either methylation or fluorination in R1 and R2).


ENUMERATION — FOCUSED MODIFICATION SETS
ChatGPT - OpenAI, 5.2 version
Prompt:

“Make 3 focused sets (R1: ~30 mods, R2: ~60 mods permuting the key nitrogen heterocycle at position 7):

1. Halogen/fluoroalkyl scan at solvent vector (BBB/logD tuning). 
2. Pocket-fill mini-frags (small rings, F/CF₃ swaps) near hydrophobic subpockets. 
3. Label-ready variants (para-F, fluoroethyl linkers) Trifluoromethyl ethers are also an interesting add here.”


STRUCTURE / FUNCTIONAL-GROUP CHECK

Prompt:
“quick question, for our modifications of the functional groups of emapunil as of now, what are the functional groups and where are they located in the structure? how many functional groups for TSPO binding are there in total for this molecule?”


CNS PROFILE
ChatGPT - OpenAI, 5.2 version
Prompt:

“let's not do pksim until we have the final set of analogs that we will be fine docking and testing. I want the script for a full adme profile of all round 1 2 and 3, With MPO, all the params listed, + logS EST, efflux rist, CNS gate and other params (i already got everything except MPO for rounds 1 and 2 but I want to rerun), I want to run a full adme profile on every single analog we have - take example from the CNS window python script we ran for 1 and 2., and I also want to append docking energy to master_stats.csv - which combined with the boundaries will give us the TBI tracer analog subset. I also want everything that we are doing for the analogs/mods, for AC5216 so I can compare and show the distinguishable impact, with all the given stats: logD₇․₄ (measured) = 3.3 (your data) Ki (TSPO) = 2.4 (your data; include units) MW (Da) TPSA (Å²) HBD, HBA, RotB cLogP (report only as a stat; don’t use it for permeability) logS (ESOL-style estimate) Efflux risk (heuristic / model flag) Docking energy (your fine docking) CNS MPO (TE-style, 0–6). We can also include sections for relative wins against AC5216 in optimization for TBI in particular (please take from literature, give detailed logic on why this is TBI specific each time - with your boundaries in mind that is - tie into the overall TBI pathology). I've already run fine docking on all TSPO tracers that have associated chemical structures AND proper data with PET metrics, Ki and logD7.4 which are clear wet lab measurements, so I believe I am good. We should claim permeability prediction in the case of logD7.4 and PKSIM stats that we run later. I already have docking energies for AC5216, but I feel like an addition of an ADME profile for AC5216 is a good idea to compare. The membrane environment of TSPO will be a great place to use logD7.4 instead of cLogP (which the presentation made the grave mistake of) in a pH changing biological environment that is at flux.”


CNS WINDOW
ChatGPT - OpenAI, 5.2 version
Prompt:

“why did you give me this window in the first place then? I want to understand the logic. You MUST use the literature given as according to TE-2052 - I want to make sure these are good for radiolabeling as well, and must pose limited efflux risk. This is for all rounds - all rounds failed in this statistical test. I don't want an ac-5216-like profile, the whole damn point of the project is to make this better than AC5216 FOR TBI - AC5216 profile may lead to false positives. We need this extra TBI tightening, and we also need to make tradeoffs based on the statistical importance of a value for example logD7.4 compared to molecular weight. Let's make some hard cutoffs - possibly run a smarter round 4, 350-550 MW, docking below 6.5, 1.5 - 4.2 log D (hard gate), TPSA < 90 A, HBD≤1, HBA ≤ 9, RotB≤10 - for tradeoff potential.”

Prompt:

“can you cross check with the literature PDF I gave you for ideal cns windows for radiotracers?”


MPO / CNS WINDOW / WEIGHTED SCORE FRAMING
ChatGPT - OpenAI, 5.2 version

Prompt:

“We also had the MPO sub-score (that was a heuristic), compared to the IAEA-informed CNS window that passed/failed analogs, and we also had a weighted average of all parameters in the framework. This should be manuscript-safe, right?”


2TCM / LOGAN / KINETIC MODELING
ChatGPT - OpenAI, 5.2 version

Prompt:

“Are you giving me misinformation? The intracellular curve starts from 10^-9 and tissue starts from 10^-7 and brain tissue sits near 10^-5.5, and intracellular is apparently almost coincidental to it. In the points distribution that also seems to be the case after the 0.03 hour timepoint. Please give me the explicitly stated equations, and script to fit the curve - account for all errors, see if you could include Vb and BPND but I'll settle for VT alone if that's the only way around.”

Prompt:

“Here is the logan plot chat: https://chatgpt.com/share/69af3305-8000-800a-adde-f0ff0d382e88.”

Prompt:

“https://www.turkupetcentre.net/petanalysis/simulation_frames.html?utm_source=chatgpt.com, https://journals.sagepub.com/doi/pdf/10.1038/sj.jcbfm.9600493 - here are the literature corroborations. can you see if you can generate a new script after recognizing these errors, and see if we can get valid data now? Alright, I figured out the issue - fP is not in the results export that I gave you from MoBi. Create a new script that only generates VT and BPND for the 2TCM model and gives the 2TCM main results as well, except remove all params that may include fP. These were also errored smiles: i already pasted the smiles and put the comments in my research journal rather than the two extra columns in my csv. haven't redownloaded yet. Recompute this - give me the code and i'll download the CSV with just these analogs (calling it error_log.csv), redock it as well - give me the pipeline again. round ligand_id smiles MW cLogP logD7.4 logD7.4_est TPSA HBD HBA RotB logS_ESOL_est efflux_risk_0to2 E_dock CNS_MPO_TE2052 Ki_note Weighted Average pass/fail_cns_window Fraction unbound R3 emap3_Bn-3,5diF_CH2CH2CF2CH3 CCN(Cc1c(F)cc(F)cc1)C(=O)Cn2c3c(cnc(n3)c4ccccc4)n(c2=O)CCC(F)(F)C 483.494 3.945 3.336 73.02 0 6 8 -4.795 0 -6.518 5.4 0.6278976667 PASS 0.0158 R3 emap3_Bn-3,4diF_OCH2CF2CH3 CCN(Cc1c(F)ccc(F)c1)C(=O)Cn2c3c(cnc(n3)c4ccccc4)n(c2=O)COCC(F)(F)C 499.493 3.877 3.191 82.25 0 7 9 -4.785 0 -6.542 5.4 0.635132 PASS 0.020099 R3 emap3_Bn-2,6diF_CH2CH2CHF2 CCN(Cc1c(F)cccc(F)1)C(=O)Cn2c3c(cnc(n3)c4ccccc4)n(c2=O)CCC(F)F 487.457 3.852 3.244 73.02 0 6 8 -4.761 0 -6.61 5.4 0.6457846667 PASS 0.01841 R3 emap3_Bn-2,6diF_CH2CH2CF2CH3 CCN(Cc1c(F)cccc(F)1)C(=O)Cn2c3c(cnc(n3)c4ccccc4)n(c2=O)CCC(F)(F)C 483.494 3.945 3.336 73.02 0 6 8 -4.795 0 -6.704 5.4 0.6348726667 PASS 0.0158”


PBPK SCORING AUDIT
ChatGPT - OpenAI, 5.2 version

Prompt:

“Audit the PBPK scoring workflow for this TSPO PET tracer project and prepare a sensitivity-analysis implementation plan as well. Do not modify any source data, candidate identities, baseline scoring definitions, or scientific assumptions yet.
The purpose of the sensitivity analysis is to test whether the candidate ranking is robust to reasonable changes in the study-defined PBPK weighting scheme. It is not to optimize weights, maximize significance, improve any candidate’s rank, or search for a favorable result.
Authoritative baseline scoring formula:
0.30*z(Brain_Plasma_60min) + 0.15*z(Brain_Plasma_30min) + 0.10*z(Brain_Plasma_90min) + 0.20*z(AUC_brain_tEnd) + 0.15*z(CNS_MPO) + 0.10*(-z(dock_score)) + brain washout penalty + plasma washout penalty
Penalty definitions:
- brain washout penalty = -0.2 if Washout_30_to_90 < 0.15 OR Washout_30_to_90 > 1.5, otherwise 0
- plasma washout penalty = -0.1 if Washout_Plasma_30_to_90 > 0.8, otherwise 0
The six continuous-component weights sum to exactly 1.0:
- Brain_Plasma_60min = 0.30
- Brain_Plasma_30min = 0.15
- Brain_Plasma_90min = 0.10
- AUC_brain_tEnd = 0.20
- CNS_MPO = 0.15
- reversed docking desirability = 0.10
Important implementation rule: represent docking internally as the desirability component -z(dock_score) with a positive weight of 0.10. Do not represent docking as a negative weight during later perturbation or renormalization.
The source spreadsheet column order A–AI is:
ligand_id, smiles, MW, logD7_4, TPSA, HBD, HBA, RotB, logS_ESOL_est, efflux, CNS_MPO, dock_score, fu, CNS_gate_pass, CL_plasma, Vss_plasma, t_half_plasma, AUC_plasma_tEnd, Cmax_plasma, AUC_brain_tEnd, Cmax_brain, C_tEnd_brain, Brain_30min, Brain_60min, Brain_90min, Plasma_30min, Plasma_60min, Plasma_90min, Brain_Plasma_30min, Brain_Plasma_60min, Brain_Plasma_90min, Washout_30_to_90, Washout_Plasma_30_to_90, Kp_brain, Final_Weighted_Score
Exact relevant Excel-column mapping:
- K = CNS_MPO
- L = dock_score
- T = AUC_brain_tEnd
- AC = Brain_Plasma_30min
- AD = Brain_Plasma_60min
- AE = Brain_Plasma_90min
- AF = Washout_30_to_90
- AG = Washout_Plasma_30_to_90
- AH = Kp_brain
- AI = Final_Weighted_Score
Kp_brain is not directly used in Final_Weighted_Score.
The original Excel formula uses rows 2:18 for every z-score calculation:
AVERAGE(range) and legacy Excel STDEV(range).
Therefore:
- exactly 17 records are used in the z-score population
- use sample standard deviation, equivalent to STDEV.S
- in pandas/numpy use ddof=1
- each scoring component must be standardized independently across those same 17 records
First task only:
1. Search the repository for the PBPK source CSV/XLSX and any related scoring outputs. There may be no existing Python scoring script because the original scoring was performed in Excel.
2. Identify the exact file that contains the 17 rows and the stored Final_Weighted_Score.
3. Verify the source columns and row count.
4. Reconstruct the baseline score exactly from the authoritative formula above.
5. Produce a candidate-by-candidate validation table containing:
   - ligand_id
   - stored Final_Weighted_Score
   - reconstructed Final_Weighted_Score
   - signed difference
   - absolute difference
6. Report the maximum absolute reconstruction error.
7. Verify that the continuous weights sum to 1.0.
8. Verify that the two penalty conditions are being applied exactly as specified.
Do not proceed to sensitivity analysis if the reconstructed scores do not match the stored baseline scores to floating-point tolerance.
A previous manual audit reproduced the 17 stored scores with maximum absolute error on the order of 6.49e-10. Treat a materially larger discrepancy as a reason to stop and investigate rather than proceeding.
Do not modify any files yet. Return:
- the source files you found
- the exact baseline reconstruction result
- any discrepancies or ambiguities
- a concise proposed implementation plan for the sensitivity analysis, but do not implement it until approved.
The baseline score was originally computed only in Excel; there may be no existing Python scoring script. Do not assume one exists. Your job is to reconstruct the Excel formula exactly in Python from the source table and verify that the resulting values match the stored Final_Weighted_Score column.”


ASKCOS API SETUP
ChatGPT - OpenAI, 5.2 version

Prompt:

“We are integrating ASKCOS v2 into this repository through its documented HTTP API. Do not deploy ASKCOS locally and do not run chemistry predictions yet.

Repository root:

`/Users/dhruv/Documents/Research/TBI`

Goal:

create the smallest possible ASKCOS API client needed for synthesis-feasibility analysis of five targets: AC-5216, A7, A3, A8, and A15.

Use the official ASKCOS v2 API documentation as authoritative. ASKCOS documents FastAPI endpoints for:

- MCTS tree search
- one-step retrosynthesis
- forward reaction outcome prediction
- reaction context/condition recommendation where available

The documented API groups include `tree-search`, `retro`, and `forward`. Non-authenticated `call-sync-without-token` endpoints may exist for some operations; authenticated endpoints may require a token from `/api/admin/token`.

First task only:

1. Determine whether the public ASKCOS deployment at `https://askcos.mit.edu` exposes its FastAPI/OpenAPI schema or usable API gateway externally.
2. Probe only harmless metadata/documentation endpoints such as:

- `/docs`
- `/openapi.json`
- equivalent API documentation/schema locations if redirected
3. Do not submit target molecules or invoke prediction endpoints yet.
4. Report:

- reachable base API URL
- whether `/openapi.json` is accessible
- available endpoint groups relevant to retrosynthesis
- exact MCTS/tree-search endpoint
- exact one-step retrosynthesis endpoint
- exact forward-prediction endpoint
- exact context/condition-recommendation endpoint if present
- which endpoints require authentication
- whether tokenless equivalents exist
5. If the public deployment does not expose these APIs, stop and report that. Do not install Docker, clone ASKCOS, or deploy local services.

If API metadata is accessible, create only:

`synthesis/askcos/api/askcos_client.py`

The initial client should:

- accept the base URL from environment variable `ASKCOS_BASE_URL`
- optionally accept an auth token from `ASKCOS_TOKEN`
- fetch the OpenAPI schema
- list relevant endpoints
- perform no prediction calls by default
- use `requests`
- have clear timeouts and error handling
- never hardcode credentials

Add:

`synthesis/askcos/api/check_askcos_api.py`

which simply verifies connectivity and prints the discovered relevant endpoints.

Do not create a larger framework, database, CLI package, MCP server, or deployment infrastructure.

Return the connectivity result and files created before doing any chemistry.”


ASKCOS — A7 AUDIT
ChatGPT - OpenAI, 5.2 version

Prompt:

“Independently verify the recent A7 ASKCOS interpretation changes made in the repository. Do not rerun ASKCOS and do not rewrite files unless you identify a factual inconsistency.

Use:

- `synthesis/askcos/A7/raw_mcts_response.json`
- `synthesis/askcos/A7/branch_analysis.json`
- `synthesis/askcos/A7/routes_summary.md`
- `synthesis/askcos/A7/key_N_difluoromethylation_step.json`

Verify:

1. the previously identified reaction does not install CHF2 because the reactant already contains `n1C(F)F`;
2. no genuine reaction in the raw tree converts a precursor lacking `C(F)F` into a product containing `n(C(F)F)`;
3. `reactions_containing_chf2` is not being mislabeled as CHF2-installation count;
4. `genuine_chf2_installation_reactions` is correctly recorded as 0;
5. all current narrative text consistently states that ASKCOS recovered plausible A7 scaffold/side-chain chemistry but did not recover direct N7-difluoromethylation;
6. JSON files remain valid and internally consistent.

Return only:

- PASS/FAIL for each check,
- any discrepancies,
- exact files requiring correction if any.

Do not rerun MCTS, forward prediction, or modify unrelated files.”


ASKCOS — A7 CORRECTION
ChatGPT - OpenAI, 5.2 version

Prompt:

“Correct the three identified A7 ASKCOS files. Do not rerun ASKCOS and do not alter unrelated files.
Files:
- synthesis/askcos/A7/branch_analysis.json
- synthesis/askcos/A7/routes_summary.md
- synthesis/askcos/A7/key_N_difluoromethylation_step.json
Required corrections:
1. In branch_analysis.json:
   - set reactions_containing_chf2 to the correct raw-tree count: 591
   - retain genuine_chf2_installation_reactions: 0
   - explicitly note that 7 apparent text-based “installations” are only equivalent SMILES notation changes (FC(F)n1... vs ...n1C(F)F) and do not represent chemical installation of CHF2
   - ensure no field or comment implies that all CHF2-containing reactions are installation events
2. In routes_summary.md:
   - correct the highlighted reaction description
   - it is N-alkylation with benzyl 2-chloroacetate
   - do not describe it as carboxylic acid coupling or amide formation
   - state that the N-CHF2 substituent is already present in the heterocyclic reactant
   - state that this reaction does not solve the unresolved N-difluoromethylation step
3. In key_N_difluoromethylation_step.json:
   - reclassify the highlighted reaction as N-alkylation of a pre-difluoromethylated heterocycle
   - set any field implying direct CHF2 installation to false / corrected wording
   - preserve the reaction metadata
   - explicitly record: direct_chf2_installation_recovered: false
   - explicitly record: genuine_chf2_installation_reactions: 0
   - note that the unresolved chemistry is preparation of the N-difluoromethylated purinone core itself
4. Validate:
   - all JSON parses correctly
   - all three files agree with one another
   - no text claims ASKCOS directly recovered N-difluoromethylation
Return:
- files changed
- exact corrected counts
- final classification
- validation status
Do not add new analyses.”


ASKCOS — A3
ChatGPT - OpenAI, 5.2 version

Prompt:

“Proceed with ASKCOS synthesis-feasibility analysis for A3 only.
Do not run A8 or A15 yet.
Use the same validated public ASKCOS API workflow used for AC-5216 and A7.
1. Locate the authoritative current A3 SMILES in the repository.
   - report source file
   - exact SMILES
   - RDKit parse result
   - RDKit canonical SMILES
   - do not use legacy IDs or substitute a web structure
2. Run one conservative MCTS search at: /api/tree-search/mcts/call-sync-without-token
   Use the same default live settings as before.
   Save:
   - synthesis/askcos/A3/request.json
   - synthesis/askcos/A3/raw_mcts_response.json
3. Determine whether complete terminal routes are present.
   If complete routes exist:
   - extract at most the top 3 complete routes.
   If no complete routes exist:
   - inspect the returned tree and extract at most the 3 most chemically relevant connected partial branches.
4. Focus on chemistry relevant to A3:
   - installation/disconnection of the benzyl-ethylamide side chain
   - formation of the purinone core
   - installation or preservation of the N-trifluoroethyl substituent
   - whether the route resembles the known AC-5216 scaffold strategy
5. For each selected route/branch report:
   - reaction SMILES
   - product → precursor sequence
   - number of represented steps
   - model/template score if available
   - plausibility if available
   - terminal buyability if available
   - whether the chemistry is straightforward, literature-like, or requires manual review
6. Specifically identify the single most uncertain transformation in the best route.
7. Do not run forward prediction or condition recommendation yet.
8. Save:
   - synthesis/askcos/A3/routes_summary.csv
   - synthesis/askcos/A3/routes_summary.md
9. Final classification:
   - strong scaffold precedent recovered
   - plausible route with one unresolved key step
   - plausible but high-risk route
   - incomplete route
   - chemically weak route
10. Do not modify unrelated project files.
Return:
- A3 structure validation
- API completion status
- number of complete routes
- top route/partial branches
- most uncertain transformation
- final synthesis-feasibility classification
- exact output files”


ASKCOS — A8
ChatGPT - OpenAI, 5.2 version

Prompt:

“Proceed with ASKCOS synthesis-feasibility analysis for A8 only.
Do not run A15 yet.
Use the same validated public ASKCOS API workflow used for AC-5216, A7, and A3.
1. Locate authoritative A8 structure
Search the repository for the current canonical A8 SMILES.
Report:
- source file
- exact SMILES
- RDKit parse result
- RDKit canonical SMILES
Do not use A8_2. Do not use legacy IDs. Do not substitute a web structure.
2. Run one conservative MCTS search
Submit A8 to:
/api/tree-search/mcts/call-sync-without-token
Use the same default live MCTS settings used for A3 and AC-5216.
Do not increase:
- search time
- max depth
- branching
- number of trees
Save:
- synthesis/askcos/A8/request.json
- synthesis/askcos/A8/raw_mcts_response.json
Preserve the raw API response exactly.
3. Determine route completeness correctly
Determine:
- total pathways returned
- number of complete terminal routes
- whether terminal leaves are marked buyable
Do not assume that every pathway is complete merely because it appears in the pathways object.
Validate completeness using the returned pathway/tree metadata.
4. Extract at most the top 3 routes
If complete routes exist:
- extract the top 3 complete routes only.
If no complete routes exist:
- extract at most the 3 most chemically relevant connected partial branches.
For each selected route/branch report:
- route index
- number of steps
- product → precursor sequence
- reaction SMILES for each step
- terminal starting materials
- buyability if provided
- pathway score if provided
- reaction/template scores if provided
- plausibility if provided
- reaction class/template where available
Do not invent unavailable fields.
5. Compare against the established scaffold logic
Assess whether the route uses recognizable chemistry related to:
- the AC-5216 purinone scaffold
- the benzyl/ethylamide side-chain strategy
- the corresponding A8-specific substituent pattern
Identify which parts have strong scaffold precedent and which are genuinely A8-specific.
6. Identify the single most uncertain transformation
For the best route, identify the one transformation that deserves manual literature review.
Do not choose the step solely because it has the lowest numerical model score.
Base this on:
- unusual bond construction
- regioselectivity
- chemoselectivity
- unusual heterocycle functionalization
- potentially difficult precursor preparation
If all steps are routine and strongly analogous to AC-5216/A3 chemistry, say so.
7. Guard against reaction misclassification
For any claimed key transformation:
- explicitly compare reactant and product structures
- verify that the claimed substituent is actually installed in that step
- do not infer transformation type from string matching alone
This is required because the A7 audit showed that equivalent SMILES notation and pre-existing substituents can create false transformation classifications.
8. No forward prediction yet
Do not run:
- forward prediction
- context/condition recommendation
- additional MCTS searches
We will decide whether any specific step needs validation after reviewing the routes.
9. Save compact outputs
Save:
- synthesis/askcos/A8/routes_summary.csv
- synthesis/askcos/A8/routes_summary.md
The CSV should contain one row per selected route or clearly separated route-step records.
10. Final synthesis-feasibility classification
Use exactly one:
- strong scaffold precedent recovered
- plausible route with one unresolved key step
- plausible but high-risk route
- incomplete route
- chemically weak route
Give a 2–4 sentence explanation.
11. Validation
Before finishing:
- verify JSON parsing
- verify A8 identity
- verify route completeness
- verify that route descriptions match actual reaction SMILES
- verify that no claimed transformation is based only on SMILES text representation
Do not modify unrelated project files.
Return:
1. A8 structure validation
2. API completion status
3. number of complete routes
4. top 3 routes or partial branches
5. single most uncertain transformation
6. final feasibility classification
7. validation status
8. exact output paths”


ASKCOS — A15
ChatGPT - OpenAI, 5.2 version

Prompt:

“Proceed with ASKCOS synthesis-feasibility analysis for A15 only.
Use the same validated public ASKCOS workflow used for AC-5216, A3, A7, and A8.
1. Locate the authoritative current A15 SMILES in the repository.
   - report source file
   - exact SMILES
   - RDKit parse result
   - RDKit canonical SMILES
   - do not use any legacy-ID structure
2. Run one conservative MCTS request using: /api/tree-search/mcts/call-sync-without-token
   Use the same default live settings used previously.
   Save:
   - synthesis/askcos/A15/request.json
   - synthesis/askcos/A15/raw_mcts_response.json
3. Determine:
   - total pathways
   - complete terminal routes
   - buyability of terminal leaves
   - total chemical and reaction nodes
   Verify completeness from the actual pathway/tree metadata.
4. Extract at most the top 3 complete routes.
   If no complete routes exist, extract at most the 3 most chemically relevant connected partial branches.
5. For each selected route report:
   - number of steps
   - product → precursor sequence
   - reaction SMILES
   - reaction/template scores
   - plausibility
   - reaction class/template if available
   - terminal starting materials
   - buyability
6. Compare the route with established AC-5216-like scaffold chemistry.
   Identify:
   - standard scaffold-building transformations
   - A15-specific transformations
   - whether the unusual A15 substituent introduces a genuinely new synthetic challenge
7. Identify the single most uncertain transformation in the best route.
   Base this on chemistry, not merely the lowest model score.
   Explicitly inspect:
   - regioselectivity
   - chemoselectivity
   - electrophile/nucleophile compatibility
   - heterocycle functionalization
   - precursor accessibility
8. Guard against the error encountered for A7.
   For every claimed substituent-installation reaction:
   - compare reactant and product connectivity
   - confirm that the substituent is actually newly installed
   - do not infer transformations from SMILES substring differences alone
9. Do not run:
   - forward prediction
   - condition recommendation
   - additional MCTS searches
10. Save:
- synthesis/askcos/A15/routes_summary.csv
- synthesis/askcos/A15/routes_summary.md
11. Use exactly one final classification:
- strong scaffold precedent recovered
- plausible route with one unresolved key step
- plausible but high-risk route
- incomplete route
- chemically weak route
12. Validate:
- JSON parses
- A15 identity
- route completeness
- terminal buyability
- reaction descriptions against actual molecular connectivity
Do not modify unrelated files.
Return:
1. A15 structure validation
2. API completion status
3. number of complete routes
4. top 3 routes or partial branches
5. most uncertain transformation
6. final synthesis-feasibility classification
7. validation status
8. exact output paths”


ASKCOS — AC-5216 CORRECTION

Prompt:

“Correct the stale AC-5216 ASKCOS derived summaries to agree with the independently audited raw MCTS graph.
Use the raw response as authoritative: synthesis/askcos/AC-5216/raw_mcts_response.json
The audited result is:
- total pathways: 200
- complete terminal routes: 200
- buyable-terminal routes: 200
Identify all existing AC-5216 derived summary files that incorrectly report zero complete routes.
Update only those derived files.
Preserve the earlier partial-route chemistry discussion if it is still factually useful, but clearly distinguish it from the now-verified complete pathway count.
Do not rerun ASKCOS. Do not modify the raw API response. Do not alter the master summary unless a consistency check shows it needs correction.
After editing, validate:
- all AC-5216 derived summaries agree with the raw graph;
- master summary agrees with AC-5216 derived summaries;
- JSON remains valid;
- no statement claims zero complete AC-5216 routes.”


MD STATISTICS — AUDIT
ChatGPT - OpenAI, 5.2 version

Prompt:

“Audit the replicated MD statistics and figure pipeline for this TSPO project. Do not change scientific definitions or endpoint selection yet.

Study design:

- Candidates: A3, A7, A8, A15, AC-5216
- Final target design: n=5 independent 10 ns trajectories per complex
- Statistical unit: one independent trajectory
- Individual trajectory frames are autocorrelated and must never be treated as independent replicates

Prespecified primary endpoints:

1. mean fixed-pocket contact count
2. mean ligand COM-to-fixed-pocket-center distance
3. percentage of frames with >=10 fixed-pocket contacts

Planned primary analysis:

- show all replicate-level values
- mean ± SD
- Kruskal-Wallis omnibus test for each primary endpoint
- exact two-sided Mann-Whitney U comparisons of each analog versus AC-5216 only
- Holm correction across the four analog-vs-reference comparisons within each endpoint
- Cliff’s delta and Hedges’ g effect sizes
- no frame-level inferential statistics
- all inferential tests labeled exploratory
- secondary MD endpoints remain descriptive unless explicitly approved

First task: inspect the existing aggregation, statistics, and plotting scripts and return a concise implementation plan. Identify any statistical, reproducibility, path, naming, or coding issues. Do not modify files yet.”


MD STATISTICS — IMPLEMENTATION
ChatGPT - OpenAI, 5.2 version

Prompt:

“Implement the audit with publication priority. Make analyze_md_replicate_statistics.py the authoritative statistics script and archive/remove the duplicate. Update the aggregation and statistics pipeline to support exactly 5 expected replicates per candidate. Restrict inferential testing to the three prespecified primary endpoints only: mean fixed-pocket contacts, mean COM-to-fixed-pocket-center distance, and percentage of frames with >=10 fixed-pocket contacts. Remove all-pairs inferential testing from the authoritative workflow; retain only four analog-vs-AC-5216 comparisons per endpoint. Use endpoint-specific Holm correction across those four comparisons. Keep secondary endpoints descriptive only. Make sure that there is no p-hacking, significance hunting, and unethical techniques used. It should survive a full peer review process.

Add hard validation for candidate set, replicate IDs 1–5, unique candidate–replicate keys, finite endpoint values, exact frame count and time coverage, and ambiguous input CSV matches. Explicitly sort by replicate ID. Remove the replicate-rank table. Add tie detection for Mann–Whitney: exact two-sided when no cross-group ties are present; asymptotic/tie-corrected otherwise, with the method recorded in output.

Add a three-panel primary figure showing all trajectory-level points and mean ± SD, with no significance stars. Add a lightweight provenance manifest containing candidate, replicate, seed if known, source file, frame count, time range, and analysis script/version.

Add regression tests for Holm adjustment, Cliff’s delta direction, Hedges’ g direction, duplicate/missing trajectories, candidate/replicate validation, and prevention of frame-level inference.

Do not alter the scientific endpoint definitions or statistical plan. Do not add new hypothesis tests. Keep the implementation minimal and publication-focused.”
